New Guidelines Recommend Sebetralstat: Expert Discusses Transition From Injectable to Oral Therapy скачать в хорошем качестве

New Guidelines Recommend Sebetralstat: Expert Discusses Transition From Injectable to Oral Therapy

Updated hereditary angioedema (HAE) guidelines emphasize early, patient-controlled on-demand treatment and individualized therapy selection. In this interview, Mauro Cancian, MD, PhD, discusses how clinicians should approach transitioning patients from injectable therapies to the oral plasma kallikrein inhibitor sebetralstat following results from the phase 3 KONFIDENT trial. Cancian explains the practical considerations behind switching therapies, including treatment burden, patient perception of injectable versus oral efficacy, and the importance of early dosing at symptom onset. He also addresses real-world data needs, durability of response, and unanswered questions in pediatric populations. This discussion offers clinically relevant insights for allergists and immunologists navigating evolving HAE management strategies. Read more: https://www.hcplive.com/view/transiti... Key highlights: 00:07: Considerations when guiding a potential transition to an oral HAE option 04:22: Limitations of the KONFIDENT trial 08:00: Unanswered questions for children under 12 years old #allergy #hae